New Product: VICAM’s New DON-NIV WB Immunoaffinity Column Significantly Enhances Laboratory Analysis of Mycotoxin

VICAM’s New DON-NIV WB Immunoaffinity Column Significantly
Enhances Laboratory Analysis of Mycotoxins

Waters Corporation (NYSE:WAT) today announced that VICAM®, a Waters® Business, introduced the DON-NIV™ WB Immunoaffinity (IA) column, the only IA column on the market to simultaneously screen for deoxynivalenol (DON) and nivalenol (NIV). Coupled with liquid chromatography analysis, the DON-NIV WB column provides over 90% recovery of both DON and NIV and doubles the productivity of commercial, government, and food safety research laboratories.

"The new DON-NIV WB column provides rapid and simple sample preparation using the superior strength of monoclonal antibody technology. DON and NIV are analyzed simultaneously in the same sample, facilitating efficient research and more effective risk management for industry," said Dr. Stephen Powers, Head of Research & Development for VICAM.

"DON was the first trichothecene mycotoxin to be regulated by many countries. Increased interest in related toxins such as NIV drives the need for improved technologies," comments Marjorie Radlo, General Manager, Director of Operations, for VICAM.

DON and NIV are trichothecene mycotoxins produced by fusarium molds. Animal feeds which are contaminated with fusarium toxins cause feed refusal, weight loss, vomiting and diarrhea – resulting in significant health, production, and economic risks. NIV has also been linked to lung and brain hemorrhage and bone marrow injury through disruption of DNA and protein synthesis.

Visit Waters Corporation for more information on the New DON-NIV WB Immunoaffinity Column